ESMO 2026 Lung Cancer Highlights: DeLLphi-305, SAFFRON, KRASCENDO-1, PERSEE
From Oncology Brothers: Practice-Changing Cancer Discussions · · 27 min
This plays from the publisher's own server. We do not host a copy.
Description
Welcome back to the Oncology Brothers podcast! In this episode, we discussed practice changing/informing studies from the ESMO 2026 conference, focusing on the latest advancements in lung cancer treatment.
Join us as we welcomed Dr. Hossein Borghaei, a thoracic medical oncologist from the Fox Chase Cancer Center, to discuss 4 key studies that could change clinical practice:
- DeLLphi-305: how the combination of durvalumab and tarlatamab after chemotherapy has led to a remarkable increase in median overall survival (OS) for patients with extensive-stage small cell lung cancer (ES-SCLC)
- SAFFRON: Learn about the efficacy of osimertinib combined with savolitinib for EGFR-mutated lung cancer patients with MET overexpression, showing significant improvements in progression-free survival (PFS) and OS compared with traditional chemotherapy
- KRASCENDO-1: We explored the new KRAS G12C inhibitor, divarasib, and its promising results against established treatments like sotorasib and adagrasib, highlighting its favorable toxicity profile
- PERSEE: Talked about the ongoing debate on whether chemotherapy should be added to immunotherapy for patients with high PD-L1 scores, as new data suggests potential benefits
Tune in for an insightful discussion that aims to keep you informed on the latest in oncology and improve patient care.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• X/Twitter: https://x.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#LungCancer, #ESMO2026, #NSCLC, #SCLC, #OncologyBrothers
Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem